Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 54

Results For "Research"

2022 News Found

AbCellera and Biogen collaborate on neurological antibody therapy
News | March 12, 2024

AbCellera and Biogen collaborate on neurological antibody therapy

AbCellera will receive an upfront payment and is eligible to receive additional milestone payments


CAPFIMS to provide opportunity for medical graduates and specialists to serve in the medical cadre of CAPFs
Policy | March 11, 2024

CAPFIMS to provide opportunity for medical graduates and specialists to serve in the medical cadre of CAPFs

The Cabinet has approved budgetary support of Rs. 2207.50 crore in the 15th Finance Commission Cycle to run CAPFIMS as a campus of AIIMS, New Delhi.


India approves Rs. 10,300 crore for AI Mission
Digitisation | March 08, 2024

India approves Rs. 10,300 crore for AI Mission

The investment will catalyse various components of the IndiaAI Mission


Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh
Biotech | March 07, 2024

Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh

India has reached to nearly 6,000 bio-startups from 50 in the past 10 years


Sakar's oncology unit receives EU GMP approval
Drug Approval | March 07, 2024

Sakar's oncology unit receives EU GMP approval

The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters


Venus Remedies awarded its first incentive of Rs.7.50 crore under PLl scheme
Policy | March 07, 2024

Venus Remedies awarded its first incentive of Rs.7.50 crore under PLl scheme

The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics


Dr. Lal PathLabs CEO Bharath Uppilliappan steps down
People | March 07, 2024

Dr. Lal PathLabs CEO Bharath Uppilliappan steps down

Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO


BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends
Diagnostic Center | March 06, 2024

BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months


Dr. Mandaviya addresses Governing Council Meeting of the ICMR
News | March 04, 2024

Dr. Mandaviya addresses Governing Council Meeting of the ICMR

ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research